Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial
Wolfe et al., medRxiv, doi:10.1101/2024.11.11.24317127
https://c19early.org/wolfe.html